Share This Page
Drugs in ATC Class D01AE
✉ Email this page to a colleague
Drugs in ATC Class: D01AE - Other antifungals for topical use
| Tradename | Generic Name |
|---|---|
| MAOLATE | chlorphenesin carbamate |
| HALOTEX | haloprogin |
| REZIPAS | aminosalicylic acid resin complex |
| EXSEL | selenium sulfide |
| SELENIUM SULFIDE | selenium sulfide |
| SELSUN | selenium sulfide |
| CICLOPIROX | ciclopirox |
| >Tradename | >Generic Name |
ATC Class D01AE: Market dynamics and patent landscape for “Other antifungals for topical use”
What is D01AE, and how does the market behave?
ATC D01AE is a basket category within topical antifungals. It covers “other antifungals for topical use” that do not sit in the major, fully dominant sub-classes (typically allylamines, azoles, and other well-established groupings). As a result, D01AE market dynamics are shaped by:
- Product mix rather than single-drug dominance. D01AE tends to include multiple small-to-mid franchises and reformulated or niche mechanisms, not a single blockbuster scaffold.
- Brand and supply-chain leverage. In many markets, the category’s top line is driven by brand incumbents, generic entry timing, and stable distribution rather than rapid innovation cycles.
- High payer and retail sensitivity. Topical antifungals often face tight reimbursement or OTC pressure. That limits price headroom and increases the value of differentiation that translates into lower cost-per-treatment (shorter regimens, better adherence, better tolerability).
- Label-driven penetration. Uptake correlates strongly with the breadth of approved indications across common dermatomycoses (tinea pedis, tinea corporis, tinea cruris) and with evidence that supports consistent mycology outcomes.
- Low switching cost for clinicians and consumers. Generic substitution and parallel switching behavior reduce the practical market impact of incremental reformulations unless they deliver clear clinical advantages or convenient dosing (e.g., fewer applications, improved skin tolerability).
Commercial implication: For D01AE, growth is usually additive (new entries, expanded claims, or geography-level scaling) rather than displacement of entrenched actives in mainstream topical antifungal segments.
What patent themes matter in D01AE?
Across D01AE, patent portfolios typically cluster into four buckets. Each bucket maps to a commercial tactic: line extension, lifecycle defense, or delayed generic entry.
1) Polymorph, hydrate/solvate, and solid-state form
- Focus: improved stability (heat, humidity), better dissolution/availability, and shelf-life extensions.
- Commercial payoff: supports product lifecycle management and can extend market exclusivity even when the core active is old.
2) Formulation innovation (vehicles, penetration enhancers, controlled release)
- Focus: topical delivery, retention on keratinized tissue, reduced irritation, and regimen simplification.
- Commercial payoff: supports differentiation against generics and helps justify label expansions or OTC positioning.
3) Use patents (indications, dosing regimens, and patient subsets)
- Focus: new indications, new dosing intervals, and evidence-backed treatment schedules.
- Commercial payoff: can extend value without re-inventing chemistry.
4) New chemical entities or new salts/derivatives
- Focus: active scaffold improvement, altered spectrum, or improved tolerability.
- Commercial payoff: higher risk but can reset exclusivity windows if the novelty survives novelty and obviousness challenges.
Which “other antifungals” actives commonly anchor D01AE portfolios?
D01AE can include actives such as ciclopirox, undecylenic acid variants, and older topical antifungals in modern formulations, depending on country-specific ATC mappings and updates. From a patent-landscape perspective, that means:
- Some incumbents have deep legacy IP that will mostly have expired in major jurisdictions.
- The remaining value often sits in reformulation patents rather than original compound patents.
- Generic entry pressure is persistent, so the “active patent” is often the newest formulation or use claim.
Where are the major exclusivity risks for the category?
D01AE risk tends to come from three directions:
- Generic substitution after loss of patent protection for the active and any key formulation patents.
- Parallel claims invalidation risk: reformulation claims can be attacked via obviousness based on prior art vehicles, penetration enhancers, and dosing norms.
- Regulatory pathway timing: abbreviated approval pathways plus bioequivalence/clinical bridging can accelerate entry when exclusivity expires.
Commercial implication: Investors and R&D planners should assume that most markets will see a succession of generic launches once the newest formulation IP breaks, unless the sponsor has multiple overlapping, defensible claim families with staggered expiry.
How does patent strategy typically look for D01AE innovators?
Successful D01AE portfolios are usually built as “stacked defenses”:
- Multiple jurisdictions with region-specific claim drafting and local prosecution outcomes.
- Continuation and divisional depth (where available) to preserve fallback claim positions.
- Formulation families that start early and mature close to approval to maximize use as infringement leverage against generic filing readiness.
- Regimen or use patents that are tied to clinical data and label language.
What does the patent landscape imply for pipeline opportunity?
Given how the category is populated (often with mature actives), pipeline opportunity concentrates on:
- Topical performance differentiation that is measurable: tolerability, adherence, skin retention, penetration depth, and regimen length.
- Clear clinical endpoint superiority that supports label expansion, not only improved pharmacokinetics.
- Claim durability: draft formulation claims to avoid the “mere combination” or “obvious carrier” problem.
Key product and IP dynamics to map in due diligence
For a D01AE diligence package, the highest-signal artifacts are:
- Every granted formulation claim and its exact scope (vehicle composition, polymer system, penetration enhancer type and level, emulsifier strategy, release mechanism, pH/viscosity constraints).
- “Orange book equivalent” listings or national regulatory linkage records where relevant, tied to product presentations and strengths.
- Dosing and indication claim sets: regimen patents tend to be narrower but can block or delay certain generic labels.
- Counterpart litigation history: invalidations, settlements, and claim constructions.
Key Takeaways
- D01AE “other topical antifungals” behaves like a portfolio category driven by product mix, formulation differentiation, and label leverage, not by a single dominant blockbuster mechanism.
- Lifecycle value in D01AE typically resides in formulation and use patents, with original compound IP often already expired in major markets.
- Generic substitution and claim-strength variability are the core risks; reformulation claims must be drafted with defensible scope to avoid obviousness and prior-art attacks.
- The best R&D and investment targets in D01AE are those with measurable topical performance advantages tied to durable, jurisdiction-specific claim strategy.
FAQs
1) Does D01AE have a dominant “blockbuster-like” patent profile?
Usually no. D01AE is generally fragmented across multiple niche or reformulated actives, so exclusivity tends to be stacked across several smaller claim families rather than dominated by a single compound.
2) Are formulation patents more important than compound patents in D01AE?
They often are. For mature actives in “other antifungals,” the incremental differentiation and exclusivity leverage usually sit in formulation and use claims rather than the original discovery chemistry.
3) What claim types most often block generic launches in D01AE?
The most common blocking claims are specific vehicle/vehicle-component formulations and narrowly defined dosing regimens or indications that align with clinical evidence and label language.
4) Why does D01AE face higher substitution risk than prescription-heavy categories?
Topical antifungals face low switching costs and often OTC or near-OTC dynamics, which accelerates generic uptake when exclusivity expires.
5) What is the most actionable patent-screening step for D01AE diligence?
Map granted formulation and use claims by presentation and strength, then tie them to regulatory linkage or equivalent databases and any litigation outcomes.
References
[1] World Health Organization. (n.d.). ATC classification. https://www.whocc.no/atc/
More… ↓
